  Protein aggregates in the brain play a central role in cognitive decline and
structural damage associated with neurodegenerative diseases. For instance, in
Alzheimer's disease the formation of Amyloid-beta plaques and tau proteins
neurofibrillary tangles follows from the accumulation of different proteins
into large aggregates through specific mechanisms such as nucleation and
elongation. These mechanisms have been studied in vitro where total protein
mass is conserved. However, in vivo, clearance mechanisms may play an important
role in limiting the formation of aggregates. Here, we generalise classical
models of protein aggregation to take into account both production of monomers
and the clearance of protein aggregates. Depending on the clearance model, we
show that there may be a critical clearance value above which aggregation does
not take place. Our result offers further evidence in support of the hypotheses
that clearance mechanisms play a potentially crucial role in neurodegenerative
disease initiation and progression; and as such, are a possible therapeutic
target.
